ATV.ASX BOT.ASX EYE.ASX SDI.ASX DRO.ASX

Activeport Secures Major Contract with Ishan Technologies

Activeport Group Ltd has secured a strategically significant contract with Ishan Netsol Pvt Ltd, a leading Indian ICT provider, to deliver its cutting-edge software-defined networking and network orchestration technology. This partnership will transform Ishan Technologies' network infrastructure, automating connectivity for more than 12,000 edge devices and serving their 85,000-strong customer base from over 100 locations in India.

The project marks the first large-scale deployment of Activeport's new Network Operations Centre (NOC) module, featuring robust inventory management plus assurance and alarm correlation capabilities to enhance network reliability and performance. Additionally, a customised self-service portal will empower Ishan's customers with greater autonomy, enabling seamless ordering, modification, and upgrading of network services, significantly improving the overall customer experience.

The strategic partnership with Ishan Technologies, a leading Indian ISP, is significant for Activeport as it establishes a high-profile collaboration with a major player in a rapidly growing market, enhancing Activeport's credibility and visibility in the booming Indian telecommunications industry. This project also showcases Activeport's ability to deliver solutions for complex, last-mile connectivity challenges, positioning the company as a leader in last-mile network orchestration and strengthening its competitive edge in the industry.

Botanix Provides Sofdra Launch Update

Botanix Pharmaceuticals has provided a positive update on the launch of its lead product Sofdra, reporting strong demand, growing prescriber base, and increasing refill rates. The company has reported gross sales of approximately $25 million AUD since January 2025, with increases month over month.

Sofdra has achieved important milestones, including expanding its prescriber base to over 2,300 unique prescribers in June 2025, and having over 16,000 prescriptions filled across 6,700 patients from launch to 30 June 2025. The refill rate for Sofdra has exceeded the industry average, with patients starting the medication in February 2025 already receiving 3.4 fills on average, compared to the industry average of 2 fills per year.

Botanix is making strategic investments to further accelerate Sofdra's growth, including expanding the sales team and increasing the number of territories. The company is also maintaining a digital presence and implementing a speaker program and medical education initiatives to support the launch. Botanix Executive Chairman Vince Ippolito expressed his satisfaction with Sofdra's performance, stating that the launch trajectory is trending positively and the company expects continued growth.

Record Revenues for FY25

Nova Eye Medical Limited has reported a record sales result for the financial year ended 30 June 2025. Group revenue for FY25 reached A$28.8 million (US$18.4 million), up 21% (in constant currency) from FY24. The key drivers of this record performance include US sales of US$14.2 million, up 25% with the iTrack™ Advance device delivering six consecutive half-years of revenue growth.

Second half FY25 sales reached A$15.7 million (US$10 million), up 46% on the prior corresponding period (in constant currency) and in line with guidance. Q4FY25 sales of A$8.4 million (US$5.4 million) were the highest on record. The record result underscores the continued adoption of iTrack™ Advance and growing global recognition of Nova Eye's technology. Nova Eye expects revenue growth to continue in FY26.

Trading update June 2025

SDI Limited, a leading dental technology company, has provided a trading update for the twelve months ended 30 June 2025. The company reported total sales of $111.0 million, marginally down 0.2% compared to the prior corresponding period. Gross profit margins improved to 63.0%, up from 62.1% in the prior year, driven by ongoing production efficiencies and product mix.

Net Profit after Tax (NPAT) is expected to be in the range of $10.0 million to $10.4 million, compared to $10.4 million for the prior corresponding period. The company also provided an update on the Montrose project, with construction tenders received and the planning permit approval progressing well. The Board has resolved that the project will be fully funded by a combination of sale and lease back of the current Bayswater premises and debt.

$11.7 million DoD Research Contract

DroneShield Limited has been awarded a follow-on 2-year R&D contract worth $11.7 million by a Five Eyes Department of Defence (DoD). This follows the successful completion of the earlier $9.9 million contract announced on 4 July 2023 from the same DoD customer. DroneShield has previously received 3 R&D contracts, including 2 follow-on contracts, from this DoD customer in November 2020, June 2021, and June 2023 totalling approximately $14.4 million.